ATM and melanoma: Downregulation of ATM in MAPKi resistant melanomas compared with the treatment-naïve tumors was confirmed by database analysis of mRNA sequencing data from matched melanoma samples before and after either BRAFi resistance or BRAFi/MEKi dual resistance development published by Hugo and colleagues (21–23).